Mengyang Di, MD, PhD
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mengyang Di, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:08 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07731789 · Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaUniversity of Washington · recruiting · Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma · principal investigator
- Ph2NCT07097363 · Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington · recruiting · B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · principal investigator
- Ph2NCT06948786 · Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL TrialUniversity of Washington · recruiting · Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma · principal investigator
- Ph2NCT06784726 · Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TUniversity of Washington · recruiting · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.